Nov. 1, 2021– The first drug company to deny 340B drug pricing program discounts to safety-net hospitals, health centers, and clinics saw its U.S. revenues jump 26% in the third quarter of 2021, thanks in part to the higher prices it is charging for diabetes drugs sold to 340B providers. In a public financial report, Eli Lilly said its third-quarter U.S. revenue totaled … [Read more...]
Diabetes Care Bears the Brunt of Drugmakers’ 340B Restrictions
Sept. 23, 2021– The eight pharmaceutical companies that are restricting the discounts they offer through the 340B drug pricing program are blocking safety-net hospitals’ access to savings on a wide range of prescription drugs. But perhaps in no area is this more evident than when looking at the prices of diabetes drugs and the levels of lost 340B resources that otherwise would … [Read more...]
As Losses Mount, 340B Pharmacy Dispute Takes Twists and Turns
By Maureen Testoni June 29, 2021– The year-long dispute over drug companies flouting the 340B statute and denying drug price discounts to hospitals, community health centers, and public health clinics partnering with community pharmacies continues to play out in Washington and in courts around the country. Since last summer, six drug companies – Eli Lilly, Novo Nordisk, … [Read more...]
Senate Report Blasts Insulin Makers for High Prices
January 21, 2021– A new, bipartisan report from a key congressional committee is sharply critical of the three major drug manufacturers that sell insulin in the U.S. The companies – Eli Lilly, Novo Nordisk, and Sanofi – already have been all over the news recently for their pricing behavior. They also are the ringleaders of a group of drug companies that are circumventing … [Read more...]
Keeping Diabetes in Check With 340B’s Help
November 25, 2020 – Chicago patient Hanan Tadros was struggling to manage her diabetes and her multiple other chronic conditions. That all started to change when she received diabetes education and medication therapy management services at UI Health in Chicago, resources available through the 340B drug pricing program. “They taught me how to take my insulin and they taught … [Read more...]
Faces of 340B: Putting Insulin Within Reach
May 15, 2020 – Patient Debra Abercrumbie remembers that when she first came to MetroHealth in Cleveland, her hemoglobin A1C levels were “out of control,” and she would need to start managing them better if she were going to improve her health while living with her diabetes. Fortunately, MetroHealth had the medication assistance and care coordination that she required, in large … [Read more...]
340B Means Better Diabetes Care
May 8, 2020— The threat of chronic diseases such as diabetes has not taken a break during the nation’s response to the COVID-19 pandemic. More than one in 10 Americans are living with diabetes, with typically underserved populations hit hard not only by the disease but also by the life-threatening complications that can come with it. The pandemic only serves to make the … [Read more...]